All In Biotech

Free tool

FAERS Monitor: Agamree

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215239 or its brand name (Agamree, Vamorolone). Reports on generic versions are filed under their own applications.

Reports

1,745

Serious

453

26% of reports

Hospitalization

210

Death reported

32

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • weight increased283
  • product dose omission issue120
  • vomiting110
  • asthenia84
  • pyrexia74
  • influenza72
  • fatigue71
  • duchenne muscular dystrophy67
  • abdominal pain upper66
  • increased appetite65
  • diarrhoea63
  • headache62
  • fall61
  • condition aggravated60
  • abdominal discomfort57

Reports by year received

View as table
YearReports
20222
20233
2024377
2025849
2026514

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,414 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
duchenne muscular dystrophySignal6731089.119814.7573,641
increased appetiteSignal6541.132.42,499
weight increasedSignal28315.313.73,790
influenzaSignal727.86.2421
product dose omission issueSignal1204.94.1376
abdominal discomfortSignal574.13.2131
abdominal pain upperSignal663.93.1139
vomitingSignal1102.82.4130
astheniaSignal842.72.289
pyrexiaSignal742.62.171
condition aggravatedSignal602.41.947
fallSignal612.21.740
headache621.20.92
diarrhoea631.20.92
fatigue711.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.